Previous 10 |
In a re-examination of its original recommendation released in December 2018, the European Medicines Agency's advisory group CHMP confirms its view that omega-3 fatty acid medicines containing a combination of an ethyl ester of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA...
BEDMINSTER, N.J., March 26, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, April 2, 2019 at 8:00 a.m. ...
- Presentation with live audio webcast Tuesday, March 19 th at 2:30 PM PT - Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer , will present at the 31 st Annual ROT...
Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 27,272,727 shares of its common stock, offered at...
Matinas BioPharma (NYSEMKT: MTNB ) has slipped 11.7% postmarket after launching a public offering of common stock. More news on: Matinas BioPharma Holdings, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the ...
BEDMINSTER, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed a prominent cardiovascular medical and clinical development expert, James (“Terry”) J. ...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...